Mauna Kea's share price is soaring on the Paris Bourse this Friday, following the publication of very strong first-quarter sales figures.

The stock is currently up 21.9%, by far the biggest gainer on the Paris market, bringing its year-to-date gains to over 75%.

Trading volumes on the stock are particularly buoyant, and are already almost ten times their daily average for the last four days.

The laser endomicroscopy specialist last night reported sales of 4.2 million euros for the first three months of the year, up 121%.

The company explains that it benefited from the first license and technology royalty revenues from its joint venture with Tasly Pharmaceutical, which alone reached 2.8 million euros in the quarter.

'This is an important milestone for Mauna Kea, confirming that the partnership strategy we announced at the end of 2021 is a source of value for our shareholders', stresses CEO Sacha Loiseau.

The executive stresses that the company is looking to continue signing new strategic partnerships in order to further expand the markets for Cellvizio, its cellular imaging platform.

Copyright (c) 2023 CercleFinance.com. All rights reserved.